Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2014
06/17/2014CA2628306C Immunostimulatory oligonucleotide-based compounds with glycerol-linked dinucleotides and modified guanosines at cpg and uses thereof
06/17/2014CA2622603C Method for preparing immunoglobulin libraries
06/17/2014CA2601936C Epidermal growth factor receptor mutations
06/17/2014CA2451740C Composition comprising wenguanguo extracts, methods for preparing same and uses thereof
06/17/2014CA2411912C Compositions and methods for treatment of candidiasis
06/17/2014CA2370306C Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
06/13/2014CA2799804A1 P16ink4a derived peptides for prophylaxis and therapy of hpv-associated tumors and other p16ink4a expressing tumors
06/13/2014CA2799803A1 Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
06/12/2014WO2014089570A1 Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
06/12/2014WO2014089500A1 A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
06/12/2014WO2014089493A1 Antibodies against factor xii and uses thereof
06/12/2014WO2014089480A1 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
06/12/2014WO2014089416A1 Compositions comprising anti-cd38 antibodies and lenalidomide
06/12/2014WO2014089335A2 Bcma antigen binding proteins
06/12/2014WO2014089209A2 Blood-brain barrier (bbb) penetrating dual specific binding proteins
06/12/2014WO2014089193A1 Anti-fgfr2 antibodies
06/12/2014WO2014089127A1 Combination therapy for treating her2-positive cancers
06/12/2014WO2014089124A1 Immunogenic compositions for inducing an immune response for elimination of senescent cells
06/12/2014WO2014089117A1 Porcine reproductive and respiratory syndrome virus compositions and uses thereof
06/12/2014WO2014089113A1 Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
06/12/2014WO2014089111A1 Compositions and methods for antibodies targeting epo
06/12/2014WO2014089061A1 Ehrlichial invasin for immunization, diagnosis, and cell delivery
06/12/2014WO2014089036A1 Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
06/12/2014WO2014089009A1 Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses
06/12/2014WO2014088664A2 Regulating bacillus anthracis lethal factor activity via an activating epitope region
06/12/2014WO2014088087A1 Double-stranded ribonucleic acid for adjuvants
06/12/2014WO2014088040A1 Method for treating mesothelioma
06/12/2014WO2014087863A1 Anti-folr1 antibody
06/12/2014WO2014087849A1 Adjuvant for mucous membrane vaccine
06/12/2014WO2014087810A1 Anti-vasohibin 2 antibody
06/12/2014WO2014087626A1 Sema5b peptides and vaccines containing the same
06/12/2014WO2014087007A1 Plasmodium falciparum neutralizing antibodies
06/12/2014WO2014086973A1 Enhanced production of the porcine circovirus capsid protein by a baculovirus vector expression system
06/12/2014WO2014086787A1 Immunogenic composition
06/12/2014WO2014086732A2 Influenza virus reassortment
06/12/2014WO2014086365A1 Anti-pad2 antibodies and treatment of autoimmune diseases
06/12/2014WO2014058875A3 Combination therapies and uses for treatment of demyelinating disorders
06/12/2014WO2014009586A3 Vectors for transforming mycoplasma hyopneumoniae, transformed m. hyopneumoniae strains, and use thereof
06/12/2014WO2013188699A9 Compositions, methods and devices for activating an immune response
06/12/2014WO2013070776A8 Neutralizing gp41 antibodies and their use
06/12/2014WO2013059493A8 Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
06/12/2014US20140162356 Monoclonal antibodies with enhanced adcc function
06/12/2014US20140161893 Polymer blend particles for intracellular delivery of agents
06/12/2014US20140161887 Adjuvant compositions
06/12/2014US20140161839 Aminophosphinic derivatives that can be used in the treatment of pain
06/12/2014US20140161838 Yersinia spp. Polypeptides and Methods of Use
06/12/2014US20140161837 Vaccine adjuvant, vaccine composition and method for preparing a vaccine adjuvant
06/12/2014US20140161836 Carious tooth vaccine and preparation method
06/12/2014US20140161835 Staphylococcus aureus div1b for use as vaccine
06/12/2014US20140161834 Yersinia spp. Polypeptides and Methods of Use
06/12/2014US20140161833 Novel neutralizing immunogen (nimiv) of rhinovirus and its uses for vaccine applications
06/12/2014US20140161832 Composition
06/12/2014US20140161826 Non-self t-cell epitope fused to an antibody that recognises a tumour-specific cell-surface receptor and uses thereof
06/12/2014US20140161824 Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
06/12/2014US20140161820 Short-Term Surrogate Test for Investigative Drugs
06/12/2014US20140161819 Compositions Comprising Anti-CD38 Antibodies and Lenalidomide
06/12/2014US20140161818 Bystander Immune Suppression as a Predictor for Response to a Vaccine
06/12/2014US20140161816 Anti- tnf antibodies, compositions, methods and uses
06/12/2014US20140161811 Platelet derived growth factor receptor supports cytomegalovirus infectivity
06/12/2014US20140161804 Bispecific immunobinders directed against tnf and il-17
06/12/2014US20140161798 Anti-pcsk9 and methods for treating lipid and cholesterol disorders
06/12/2014US20140161797 Injectable Non-Aqueous Suspension
06/12/2014US20140161795 Method for treating a disease characterized by increased appetite
06/12/2014US20140161794 Anti-vla-4 antibodies
06/12/2014US20140161793 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
06/12/2014US20140161768 Porcine reproductive and respiratory syndrome virus compositions and uses thereof
06/12/2014US20140161724 Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides
06/11/2014EP2740798A1 Cancer treatment and/or prevention drug composition
06/11/2014EP2740796A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer
06/11/2014EP2740795A1 Cancer treatment and/or prevention drug composition
06/11/2014EP2740794A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer
06/11/2014EP2740793A1 Drug composition for cancer treatment and/or prevention
06/11/2014EP2740744A2 SP35 antibodies and uses thereof
06/11/2014EP2740743A2 Bispecific fusion antibodies with enhanced serum half-life
06/11/2014EP2740490A1 Treatment of proliferative disorders using antibodies to PSMA
06/11/2014EP2740489A1 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
06/11/2014EP2740488A1 Sequential and repeated application of four or more hiv vector gene vaccines
06/11/2014EP2739724A1 Recombinant swine influenza virus and uses thereof
06/11/2014EP2739651A1 Anti-polyubiquitin antibodies and methods of use
06/11/2014EP2739650A2 Bovine polyclonal antibody specific for human tnf
06/11/2014EP2739358A1 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
06/11/2014EP2739312A2 A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
06/11/2014EP2739311A1 Method for treating bone gap defects
06/11/2014EP2739310A1 Improved methods and compositions for modulation of olfml3 mediated angiogenesis
06/11/2014EP2739309A1 Composition comprising a tlr agonist and an antibody specific for an antigen and uses thereof as vaccine
06/11/2014EP2739308A1 Hypoallergenic variants of mal d 1, the major allergen from malus domestica
06/11/2014EP2739307A1 Vlps containing ligands and methods related thereto
06/11/2014EP2739300A2 N-terminal deleted gp120 immunogens
06/11/2014CN103857411A Methods and compositions for treating asthma using anti-il-13 antibodies
06/11/2014CN103849637A O-type foot and mouth disease virus acid-resistant mutant strain, capsid protein carried by O-type foot and mouth disease virus acid-resistant mutant strain, coding gene of capsid protein and use of O-type foot and mouth disease virus acid-resistant mutant strain and capsid protein
06/11/2014CN103849632A S1 gene of low virulent strain of infectious bronchitis and low virulent strain and application thereof
06/11/2014CN103849631A Infectious bursal disease virus subunit antigen-containing vaccine composition, preparation method and application thereof
06/11/2014CN103848915A Preparation and application of novel anti-rabies virus glycoprotein human-derived genetically-engineered antibody
06/11/2014CN103848902A Synthetic peptide vaccine and preparation method thereof
06/11/2014CN103845731A Application of anti-ST2/IL-1R4 antibody in preparing medicament for preventing and treating pruritus
06/11/2014CN103845730A Application of anti-ST2/IL-1R4 antibody in preparation of pain relieving medicament
06/11/2014CN103145853B Recombined Talpha 1-BP5 fusion peptide, gene, engineering bacteria and application
06/11/2014CN103012590B Anti-CD20 monoclonal antibody, preparation method and application thereof
06/11/2014CN103007270B Injection injected into acupoint Houhai to treat piglet diarrhea
06/11/2014CN102988983B Anti-human platelet membrane glycoprotein Ib alpha chimeric antibody pharmaceutical composition
1 ... 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 ... 1823